Study on Plasmablastic Lymphoma Patients (FIL_PlaLy)
An International Multicenter Observational Retrospective Study on Plasmablastic Lymphoma Patients
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Uffici Studi FIL
- Phone Number: +390131033153
- Email: startup@filinf.it
Study Contact Backup
- Name: Uffici Studi FIL
- Phone Number: +390131033160
- Email: gestionestudi@filinf.it
Study Locations
-
-
-
Ascoli Piceno, Italy
- Recruiting
- Ospedale C.e G. Mazzoni, U.O.C. di Ematologia
-
Contact:
- Piero Galieni, MD
- Email: piero.galieni@sanita.marche.it
-
Principal Investigator:
- Piero Galieni, MD
-
Brescia, Italy
- Active, not recruiting
- ASST Spedali Civili di Brescia, Ematologia
-
Cuneo, Italy
- Recruiting
- A.O. S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo
-
Contact:
- Claudia Castellino, MD
- Email: castellino.c@ospedale.cuneo.it
-
Principal Investigator:
- Claudia Castellino, MD
-
Florence, Italy
- Recruiting
- Azienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia
-
Principal Investigator:
- Luca Nassi, MD
-
Contact:
- Luca Nassi, MD
- Email: nassil@aou-careggi.toscana.it
-
Milan, Italy
- Recruiting
- ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia
-
Principal Investigator:
- Emanuele Ravano, MD
-
Contact:
- Emanuele Ravano, MD
- Email: emanuele.ravano@ospedaleniguarda.it
-
Milan, Italy
- Recruiting
- ASST -Fatebenefratelli - Polo Luigi Sacco Oncologia
-
Principal Investigator:
- Nicla La Verde, MD
-
Contact:
- Nicla La Verde, MD
- Email: nicla.laverde@asst-fbf-sacco.it
-
Milan, Italy
- Active, not recruiting
- Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia
-
Milan, Italy
- Active, not recruiting
- Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Ematologia
-
Monza, Italy
- Recruiting
- Fondazione IRCCS San Gerardo dei Tintori, Ematologia
-
Principal Investigator:
- Luisa Verga, MD
-
Contact:
- Luisa Verga, MD
- Email: luisa.verga@irccs-sangerardo.it
-
Novara, Italy
- Active, not recruiting
- AOU Maggiore della Caritа di Novara, SCDU Ematologia
-
Padova, Italy
- Not yet recruiting
- Azienda Ospedaliera Universitaria di Padova, Ematologia
-
Principal Investigator:
- Greta Scapinello, MD
-
Contact:
- Greta Scapinello, MD
- Email: greta.scapinello@aopd.veneto.it
-
Pagani, Italy
- Not yet recruiting
- Presidio ospedaliero A. Tortora, U.O. Onco-ematologia
-
Contact:
- Catello Califano, MD
- Email: c.califano@aslsalerno.it
-
Principal Investigator:
- Catello Califano, MD
-
Reggio Emilia, Italy
- Recruiting
- Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Ematologia
-
Contact:
- Angela Ferrari, MD
- Email: ferrari.angela@ausl.re.it
-
Principal Investigator:
- Angela Ferrari, MD
-
Roma, Italy
- Recruiting
- Policlinico Umberto I - Università La Sapienza, Istituto Ematologia, Dipartimento di Medicina Traslazionale e di Precisione
-
Contact:
- Alice Di Rocco, MD
- Email: dirocco@bce.uniroma1.it
-
Principal Investigator:
- Alice Di Rocco, MD
-
Roma, Italy
- Not yet recruiting
- Universitа Cattolica S. Cuore, Ematologia
-
Contact:
- Stefan Hohaus, Prof
- Email: stefan.hohaus@Unicatt.it
-
Principal Investigator:
- Stefan Hohaus, Prof
-
Roma, Italy
- Recruiting
- Azienda Ospedaliera Universitaria Sant' Andrea, Ematologia
-
Contact:
- Agostino Tafuri, Prof
- Email: agostino.tafuri@ospedalesantandrea.it
-
Principal Investigator:
- Agostino Tafuri, Prof
-
Siena, Italy
- Recruiting
- Azienda Ospedaliero Universitaria Senese, U.O.C. Ematologia
-
Contact:
- Emanuele Cencini, MD
- Email: cencioema@libero.it
-
Principal Investigator:
- Emanuele Cencini, MD
-
Torino, Italy
- Not yet recruiting
- A.O.U. Città della Salute e della Scienza di Torino, Ematologia Universitaria
-
Contact:
- Federica Cavallo, MD
- Email: f.cavallo@unito.it
-
Principal Investigator:
- Federica Cavallo, MD
-
Torino, Italy
- Recruiting
- A.O.U. Città della Salute e della Scienza di Torino, S.C. Ematologia
-
Principal Investigator:
- Barbara Botto, MD
-
Contact:
- Barbara Botto, MD
- Email: bbotto@cittadellasalute.to.it
-
Trento, Italy
- Recruiting
- Ospedale S. Chiara, S.S. di Ematologia
-
Principal Investigator:
- Chandrakala Toldo, MD
-
Contact:
- Chandrakala Toldo, MD
- Email: chandrakala.toldo@apss.tn.it
-
Treviso, Italy
- Active, not recruiting
- ULSS2 Marca Trevigiana, Ospedale Ca' Foncello, S.C di Ematologia
-
Vicenza, Italy
- Recruiting
- ULSS 8 Berica - Ospedale S. Bortolo, Ematologia
-
Contact:
- Marcello Riva, MD
- Email: riva.marcello83@gmail.com
-
Principal Investigator:
- Marcello Riva, MD
-
-
PN
-
Aviano, PN, Italy
- Recruiting
- IRCCS Centro di Riferimento Oncologico di Aviano, Divisione di Oncologia e dei Tumori immuno-correlati
-
Contact:
- Michele Spina, MD
- Email: mspina@cro.it
-
Principal Investigator:
- Michele Spina, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of plasmablastic lymphoma (PBL) between Jan 1st 2000, and Dec 31st 2022
- Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report
- Age > 18 years old
- Availability of complete medical records
- Availability of histopathological material requested by the study
Exclusion Criteria:
- Any other histology than PBL
- Lack of complete medical records
- Lack of histopathological material requested by the study
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Plasmablastic lymphoma patients
Patients with diagnosis (histologically confirmed) of plasmablastic lymphoma (PBL) between Jan 1st 2000 and Dec 31st 2022
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival (OS)
Time Frame: 36 months
|
OS is defined as the time from the diagnosis to death for any cause or last clinical contact for censored patients.
|
36 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ECOG-PS
Time Frame: 36 months
|
Proportion of Performance Status: from 0 (fully active) to 4 (Completely disabled)
|
36 months
|
|
Ann Arbor Stage
Time Frame: 36 months
|
Proportion of stage: from I (better) to IV (worse)
|
36 months
|
|
Kidney and/or adrenal gland involvement
Time Frame: 36 months
|
Proportion of the presence of involvement
|
36 months
|
|
Diagnostic liquor
Time Frame: 36 months
|
Proportion of the presence of liquor
|
36 months
|
|
Splenic involvement
Time Frame: 36 months
|
Proportion of spenic involvement
|
36 months
|
|
Type of chemotherapy (CHT) regimen
Time Frame: 36 months
|
Proportion of CHT administered
|
36 months
|
|
Complete remission rate (CR)
Time Frame: 36 months
|
CR at the end of treatment
|
36 months
|
|
Overall response rate (ORR)
Time Frame: 36 monts
|
ORR is defined as the proportion of patients who have a partial or complete response to therapy
|
36 monts
|
|
Progression-free survival (PFS)
Time Frame: 36 months
|
PFS is defined as time from diagnosis to progression, relapse or death for any cause and last clinical contact for censored cases,
|
36 months
|
|
Validation of IPI and CNS-IPI score by means of Cox PH regression on OS and PFS
Time Frame: 36 months
|
IPI (international prognostic Index) ranging from 0 (lower risk) to 5 points (greater risk); CNS-IPI score (Central Nervous System IPI) ranging from 0 (lower risk) to 6 points (greater risk).
|
36 months
|
|
Frequencies of HIV and EBV at relapse
Time Frame: 36 months
|
Frequencies of HIV and EBV at relapse
|
36 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Alessia Castellino, MD, UO Ematologia, AO Santa Croce e Carle, Cuneo - Italy
- Principal Investigator: Emanuele Ravano, MD, UO Ematologia, Niguarda Grande Ospedale Metropolitano, Milano - Italy.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FIL_PlaLy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.